Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09BKY
|
|||
| Former ID |
DCL000495
|
|||
| Drug Name |
Bevacizumab + Erlotinib
|
|||
| Indication | Metastatic colorectal cancer [ICD-11: 2B91; ICD-10: C19] | Phase 3 | [1], [2] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 3 | [1], [2] | ||
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0] | Phase 2 | [3], [4], [5], [6], [7], [8] | ||
| Hypopharyngeal squamous cell carcinoma [ICD-11: 2B6D.0] | Phase 1/2 | [9] | ||
| Company |
Roche
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | |||
| REF 2 | ClinicalTrials.gov (NCT00598156) Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva | |||
| REF 3 | ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health. | |||
| REF 4 | ClinicalTrials.gov (NCT00287222) Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma | |||
| REF 5 | ClinicalTrials.gov (NCT02655536) Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial | |||
| REF 6 | Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S17-23. | |||
| REF 7 | Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011 May 28;377(9780):1846-54. | |||
| REF 8 | ClinicalTrials.gov (NCT00365391) Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | |||
| REF 9 | ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | |||
| REF 10 | Clinical pipeline report, company report or official report of Roche (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.